Description

BSE permits trading in Rights Entitlements (REs) for Healthcare Global Enterprises Limited starting March 11, 2026, with renunciation period running through March 20, 2026.

Summary

BSE has permitted dealings in Rights Entitlements (REs) for renunciation of Healthcare Global Enterprises Limited effective Wednesday, March 11, 2026. The REs are tradable under scrip code 751095 (scrip ID: HCG-RE) and will be settled on a T+1 rolling, trade-for-trade basis in dematerialized form only.

Key Points

  • Rights Entitlements (REs) for Healthcare Global Enterprises Limited are tradable on BSE from March 11, 2026
  • Scrip Code: 751095 | Scrip ID: HCG-RE | ISIN: INE075I20017
  • Market Lot: 1 | Group: R
  • Settlement on T+1 Rolling Settlement basis (trade-for-trade)
  • REs are tradable in dematerialized form only
  • Trading members must inform clients that REs are not ordinary shares of the company
  • Contract notes/bills must carry a prominent disclaimer about the nature of REs
  • REs neither subscribed nor renounced before the Issue Closing Date shall lapse and be extinguished

Regulatory Changes

No new regulatory framework introduced. Trading is conducted under the existing Rights Entitlements trading guidelines as referenced in BSE notices 20200305-21 (March 5, 2020) and 20200518-34 (May 18, 2020).

Compliance Requirements

  • Trading members must inform all clients about the commencement of RE trading, specifying the ISIN (INE075I20017)
  • Members must clarify that REs must not be mistaken for ordinary shares of Healthcare Global Enterprises Limited
  • Contract notes and bills for RE purchases must prominently include a disclaimer stating that purchasing REs only entitles the holder to participate in the rights issue or renounce the REs before the issue closes
  • Members should refer to notice nos. 20200305-21 and 20200518-34 for detailed procedural requirements

Important Dates

  • RE Trading (Renunciation) Period: March 11, 2026 to March 20, 2026
  • Rights Issue Open Period: March 11, 2026 to March 25, 2026
  • RE Lapse: After March 25, 2026 (Issue Closing Date) for unsubscribed/unrenounced REs

Impact Assessment

This circular is relevant primarily to existing shareholders of Healthcare Global Enterprises Limited (HCG) who have received Rights Entitlements and wish to either renounce them on the exchange or subscribe to the rights issue. Trading members facilitating transactions in HCG-RE must ensure compliance with disclosure and disclaimer obligations. The T+1 trade-for-trade settlement reduces counterparty risk but limits netting benefits. The short renunciation window (March 11–20) requires prompt action from shareholders who do not intend to subscribe.

Impact Justification

Company-specific circular enabling trading in Rights Entitlements for HCG's rights issue; relevant to existing HCG shareholders and trading members but limited broader market impact.